Blogs (10)

D6808 is a Highly Selective c‑Met Inhibitor used for NSCLC and Gastric Cancer Research

D6808 is a highly selective and potent c‑Met inhibitor. D6808 can be used for the research of NSCLC and gastric cancers
Tivantinib is a Selective c-Met Tyrosine Kinase Inhibitor

Tivantinib is a selective and orally active inhibitor of c-MET. Tivantinib can be used for the research of cancer.
ABT-737 is a Selective and BH3 Mimetic Bcl-2, Bcl-xL and Bcl-w Inhibitor

ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor and has the potential for acute myeloid leukemia (AML) research.
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor

Crizotinib is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Anti-tumor activity.
Pelcitoclax (APG-1252) is a Bcl-2/Bcl-xl Inhibitor with Antineoplastic and Pro-Apoptotic Effects

Pelcitoclax has potent anti-tumor effects through ntrinsic mitochondrial pathway of apoptosis in cancer cells.
SIS3 is a Potent and Selective Inhibitor of Smad3 Phosphorylation

SIS3 is a selective Smad3 phosphorylation inhibitor and inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.
CPL304110 is an Orally Active and Selective FGFR(1-3) Inhibitor

CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), respectively.
BAY1082439 is an Orally Active and Selective Balanced PI3Kα/β/δ Inhibitor

BAY1082439, an orally bioavailable, selective PI3K inhibitor, inhibits mutated forms of PIK3CA and is effective in treating prostate cancer with PTEN-loss.
LCH-7749944 is a Potent PAK4 Inhibitor and Induces Apoptosis

LCH-7749944 is a potent PAK4 inhibitor and effectively suppresses the proliferation of human gastric cancer cells and induces apoptosis.
SU16f is a Selective PDGFRβ Inhibitor for Gastric Cancer Therapy

SU16f is a selective PDGFRβ inhibitor and significantly decreases the enhanced migratory ability of SGC-7901 cells by GC-MSC.

Name
Email *

	Sorry, but the email address you supplied was invalid.